- Home
- NOM vs ALXO Comparison
NOM vs ALXO Comparison
Compare NOM & ALXO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NOM
- ALXO
- Stock Information
- Founded
- NOM 1993
- ALXO 2015
- Country
- NOM United States
- ALXO United States
- Employees
- NOM N/A
- ALXO N/A
- Industry
- NOM Investment Managers
- ALXO Biotechnology: Pharmaceutical Preparations
- Sector
- NOM Finance
- ALXO Health Care
- Exchange
- NOM Nasdaq
- ALXO Nasdaq
- Market Cap
- NOM 25.0M
- ALXO 24.0M
- IPO Year
- NOM N/A
- ALXO 2020
- Fundamental
- Price
- NOM $10.78
- ALXO $0.58
- Analyst Decision
- NOM
- ALXO Strong Buy
- Analyst Count
- NOM 0
- ALXO 6
- Target Price
- NOM N/A
- ALXO $3.30
- AVG Volume (30 Days)
- NOM 6.9K
- ALXO 445.9K
- Earning Date
- NOM 01-01-0001
- ALXO 05-08-2025
- Dividend Yield
- NOM 3.39%
- ALXO N/A
- EPS Growth
- NOM N/A
- ALXO N/A
- EPS
- NOM N/A
- ALXO N/A
- Revenue
- NOM N/A
- ALXO N/A
- Revenue This Year
- NOM N/A
- ALXO N/A
- Revenue Next Year
- NOM N/A
- ALXO N/A
- P/E Ratio
- NOM N/A
- ALXO N/A
- Revenue Growth
- NOM N/A
- ALXO N/A
- 52 Week Low
- NOM $8.52
- ALXO $0.41
- 52 Week High
- NOM $10.48
- ALXO $9.40
- Technical
- Relative Strength Index (RSI)
- NOM 56.60
- ALXO 60.39
- Support Level
- NOM $10.40
- ALXO $0.52
- Resistance Level
- NOM $10.89
- ALXO $0.59
- Average True Range (ATR)
- NOM 0.13
- ALXO 0.04
- MACD
- NOM -0.01
- ALXO 0.02
- Stochastic Oscillator
- NOM 80.00
- ALXO 94.10
About NOM Nuveen Missouri Quality Municipal Income Fund
Nuveen Missouri Quality Municipal Income Fund is a diversified, closed-end management investment company operating in United States. The Fund's primary investment objective is current income exempt from both regular federal income taxes and Missouri state income taxes; its secondary investment objective is the enhancement of portfolio value. The fund invests in municipal securities as well as floating rate securities as well as derivatives such as futures, options and swap contracts to the necessary extent. Nuveen Fund Advisors, LLC acts as an investment adviser of the company.
About ALXO ALX Oncology Holdings Inc.
ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. The company is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.